Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Iveta Zapletalova"'
Autor:
Veronika Frybortova, Stefan Satka, Lenka Jourova, Iveta Zapletalova, Martin Srejber, Philippe Briolotti, Martine Daujat-Chavanieu, Sabine Gerbal-Chaloin, Pavel Anzenbacher, Michal Otyepka, Eva Anzenbacherova
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 7, p 3610 (2024)
As compounds of natural origin enter human body, it is necessary to investigate their possible interactions with the metabolism of drugs and xenobiotics in general, namely with the cytochrome P450 (CYP) system. Phytic acid (myo-inositol hexaphosphori
Externí odkaz:
https://doaj.org/article/8882ed7b9225490994babe3a277fa71b
Autor:
Martina Hüttl, Irena Markova, Denisa Miklánková, Iveta Zapletalova, Petr Kujal, Jan Šilhavý, Michal Pravenec, Hana Malinska
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Background and aims: Low-grade chronic inflammation plays an important role in the pathogenesis of metabolic syndrome, type 2 diabetes and their complications. In this study, we investigated the effects of salsalate, a non-steroidal anti-inflammatory
Externí odkaz:
https://doaj.org/article/43d18ec3736b4092867a31a16cc3da06
Autor:
Lenka Jourova, Stefan Satka, Veronika Frybortova, Iveta Zapletalova, Pavel Anzenbacher, Eva Anzenbacherova, Petra Petr Hermanova, Barbora Drabonova, Dagmar Srutkova, Hana Kozakova, Tomas Hudcovic
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
The development of inflammatory bowel disease (IBD) is associated with alterations in the gut microbiota. There is currently no universal treatment for this disease, thus emphasizing the importance of developing innovative therapeutic approaches. Gut
Externí odkaz:
https://doaj.org/article/354778228db1423bae3af4090715a4c2
Autor:
Stefan Satka, Veronika Frybortova, Iveta Zapletalova, Pavel Anzenbacher, Eva Anzenbacherova, Hana Kozakova, Dagmar Srutkova, Tomas Hudcovic, Lenka Jourova
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 19, p 11627 (2022)
Several studies have indicated the beneficial anti-inflammatory effect of butyrate in inflammatory bowel disease (IBD) therapy implying attempts to increase butyrate production in the gut through orally administered dietary supplementation. Through t
Externí odkaz:
https://doaj.org/article/481e23afe07c46c293d5e93f1579d38e
Autor:
Martina Hüttl, Irena Markova, Denisa Miklankova, Iveta Zapletalova, Martin Poruba, Zuzana Racova, Rostislav Vecera, Hana Malinska
Publikováno v:
Pharmaceutics, Vol 14, Iss 1, p 45 (2021)
The combination of plant-derived compounds with anti-diabetic agents to manage hepatic steatosis closely associated with diabetes mellitus may be a new therapeutic approach. Silymarin, a complex of bioactive substances extracted from Silybum marianum
Externí odkaz:
https://doaj.org/article/8958765974644291a660f42016709d97
Autor:
Martina Hüttl, Irena Markova, Denisa Miklankova, Iveta Zapletalova, Martin Poruba, Martin Haluzik, Ivana Vaněčkova, Hana Malinska
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 21, p 11513 (2021)
Recent studies suggest that treatment with SGLT-2 inhibitors can reduce hepatic lipid storage and ameliorate non-alcoholic fatty liver disease (NAFLD) development beyond their glycemic benefits. However, the exact mechanism involved is still unclear.
Externí odkaz:
https://doaj.org/article/5232f2e319d64d328a7424197deea0a9
Autor:
Denisa Miklankova, Irena Markova, Martina Hüttl, Iveta Zapletalova, Martin Poruba, Hana Malinska
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 14, p 7680 (2021)
Metformin can reduce cardiovascular risk independent of glycemic control. The mechanisms behind its non-glycemic benefits, which include decreased energy intake, lower blood pressure and improved lipid and fatty acid metabolism, are not fully underst
Externí odkaz:
https://doaj.org/article/7ed34ba49cc94f118bc8319975ec889d
Autor:
Hana Malinska, Iveta Zapletalova, Martin Haluzik, Denisa Miklankova, Irena Markova, Martin Poruba, Martina Hüttl, Ivana Vaněčková
Publikováno v:
International Journal of Molecular Sciences
Volume 22
Issue 21
International Journal of Molecular Sciences, Vol 22, Iss 11513, p 11513 (2021)
Volume 22
Issue 21
International Journal of Molecular Sciences, Vol 22, Iss 11513, p 11513 (2021)
Recent studies suggest that treatment with SGLT-2 inhibitors can reduce hepatic lipid storage and ameliorate non-alcoholic fatty liver disease (NAFLD) development beyond their glycemic benefits. However, the exact mechanism involved is still unclear.
Autor:
Denisa Miklankova, Jaroslava Trnovska, Irena Markova, Martin Poruba, Hana Malinska, Martina Hüttl, Iveta Zapletalova
Publikováno v:
International Journal of Molecular Sciences
Volume 22
Issue 9
International Journal of Molecular Sciences, Vol 22, Iss 4527, p 4527 (2021)
Volume 22
Issue 9
International Journal of Molecular Sciences, Vol 22, Iss 4527, p 4527 (2021)
Ovarian hormone deficiency leads to increased body weight, visceral adiposity, fatty liver and disorders associated with menopausal metabolic syndrome. To better understand the underlying mechanisms of these disorders in their early phases of develop
Autor:
Ondrej Zendulka, Iveta Zapletalova, Gabriela Dovrtelova, Natasa Hlavacova, Jan Jurica, Petr Pavek, Alejandro Carazo, Ondrej Pes, Jan Dusek, Kristyna Noskova
Publikováno v:
Drug Metabolism and Disposition. 46:913-923
The endocannabinoid system is important for many physiologic and pathologic processes, but its role in the regulation of liver cytochromes P450 (P450s) remains unknown. We studied the influence of the endocannabinoid oleamide on rat and human liver P